SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.

NEW YORK, Jan. 18, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. ("Leap" or the "Company") (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. ("Flame"). Under the terms of the merger agreement, the Company will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders. Upon approval of the transaction, each share of the Series X non-voting convertible preferred stock will be automatically converted into 1,000 shares of common stock. 

If you own Leap shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/lptx 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) Leap's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration is fair to Leap's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. 

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED